A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA

BACKGROUND: Rituximab (R) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) is the current standard therapy for diffuse large B cell lymphoma (DLBCL). Obinutuzumab (G), a glycoengineered, type II anti-CD20 monoclonal antibody, has shown activity and an acceptable safety profile...

Descripción completa

Detalles Bibliográficos
Autores principales: Sehn, Laurie H., Martelli, Maurizio, Trněný, Marek, Liu, Wenxin, Bolen, Christopher R., Knapp, Andrea, Sahin, Deniz, Sellam, Gila, Vitolo, Umberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276080/
https://www.ncbi.nlm.nih.gov/pubmed/32505213
http://dx.doi.org/10.1186/s13045-020-00900-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276080/
https://www.ncbi.nlm.nih.gov/pubmed/32505213
http://dx.doi.org/10.1186/s13045-020-00900-7

Ejemplares similares